α-Synuclein Levels in Blood Plasma from LRRK2 Mutation CarriersReportar como inadecuado




α-Synuclein Levels in Blood Plasma from LRRK2 Mutation Carriers - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

The diagnosis of Parkinson’s disease PD remains primarily a clinical issue, based mainly on phenotypic patterns. The identification of biomarkers capable of permitting the preclinical detection of PD is critically needed. α-Synuclein is a key protein in PD, with missense and multiplication mutations in the gene encoding α-synuclein SNCA having been reported in familial cases of PD, and accumulation of the protein identified in Lewy bodies LBs and Lewy neurites LNs in affected brain regions. With the objective of validating the use of α-synuclein as a clinical or progressive biomarker in an accessible tissue, we used an enzyme-linked immunosorbent assay ELISA to measure α-synuclein levels in the peripheral blood plasma of idiopathic PD and LRRK2 mutation carrier patients and compared our findings with healthy control subjects. Compared to healthy controls, we found a significant decrease in plasma total α-synuclein levels in idiopathic PD iPD patients n = 134, p = 0.010. However, the reduction was less significant in patients who were LRRK2 mutation carriers n = 32, p = 0.133. This lack of significance could be due to the small number of individuals employed in this group. No predictive value of total α-synuclein in the diagnosis of PD was found in a receiver operating characteristic ROC curve analysis. Although this is a pilot study requiring corroboration on a larger cohort of patients, our results highlight the possible use of plasma α-synuclein as a biomarker for PD.



Autor: Ana Gorostidi, Alberto Bergareche, Javier Ruiz-Martínez, José F. Martí-Massó, María Cruz, Shiji Varghese, Mohamed M. Qureshi

Fuente: http://plos.srce.hr/



DESCARGAR PDF




Documentos relacionados